 |
|
Anti-HIV drugs unlikely to stop HIV spread
March 14, 2006Researchers believe antiretroviral therapy (ART) will not be effective in stopping HIV epidemics even if it is made universally available in poorer countries, and that widespread use could even lead to an increase in the numbers infected with HIV.
Research published today in PLoS Medicine by a team from Imperial College London reveals a model which predicts how different strategies for increasing access to ART might affect HIV infection rates.
The modelling found that while ART reduces the viral load of infected individuals, thus decreasing the risk of HIV transmission, slowing disease progression allows patients to live longer, increasing the number infected and potentially the number of new infections they will cause.
Rebecca Baggaley, from Imperial College London, and one of the authors of the paper, said: "This model demonstrates that ongoing provision of prevention initiatives for stopping the spread of HIV is vital. Although ART may prove effective as part of an integrated treatment and prevention programme, including increased education and promotion of safe sex practices, it is unlikely to be effective alone.
"For a number of years, there has been significant debate about access to antiretroviral drugs, and how the high cost of these drugs has hindered many poorer countries' attempts to combat HIV epidemics. While ART is undoubtedly effective at treating AIDS patients, particularly in richer countries, without public health interventions it will not prove effective in stopping the spread of HIV in poorer countries."
The model also studied how ART treatment might affect behaviour. The researchers believe it could result in a greater spread of HIV by making infected individuals feel physically better, and more likely to be sexually active, but counselling of ART patients about risk behaviour could compensate for this to some extent. Therefore prevention initiatives aiming to decrease patients' risk taking behaviour are even more relevant.
Rebecca Baggaley added: "This study could be important in helping to ensure that limited supplies of ART are used most effectively.\\\
Imperial College London
Rebecca Baggaley, from Imperial College London, and one of the authors of the paper, said: "This model demonstrates that ongoing provision of prevention initiatives for stopping the spread of HIV is vital. Although ART may prove effective as part of an integrated treatment and prevention programme, including increased education and promotion of safe sex practices, it is unlikely to be effective alone.
"For a number of years, there has been significant debate about access to antiretroviral drugs, and how the high cost of these drugs has hindered many poorer countries' attempts to combat HIV epidemics. While ART is undoubtedly effective at treating AIDS patients, particularly in richer countries, without public health interventions it will not prove effective in stopping the spread of HIV in poorer countries."
The model also studied how ART treatment might affect behaviour. The researchers believe it could result in a greater spread of HIV by making infected individuals feel physically better, and more likely to be sexually active, but counselling of ART patients about risk behaviour could compensate for this to some extent. Therefore prevention initiatives aiming to decrease patients' risk taking behaviour are even more relevant.
Rebecca Baggaley added: "This study could be important in helping to ensure that limited supplies of ART are used most effectively.\\\
Imperial College London
Anti-HIV Drugs Current Events and Anti-HIV Drugs News RSSResearch suggests new cellular targets for HIV drug development
Focusing HIV drug development on immune cells called macrophages instead of traditionally targeted T cells could bring us closer to eradicating the disease, according to new research from University of Florida and five other institutions.
Body's anti-HIV drug explained
Humans have a built-in weapon against HIV, but until recently no one knew how to unlock its potential.
Scientists unmask key HIV protein, open door for more powerful AIDS drugs
University of Michigan scientists have provided the most detailed picture yet of a key HIV accessory protein that foils the body's normal immune response.
ABC-transporters expressed on endothelial cell membranes efflux anti-HIV drugs
Researchers at Tulane University Medical Center in New Orleans (USA) have discovered that drug-efflux pumps, belonging to the ATP-binding cassette (ABC) transporter family, are constitutively expressed on vascular endothelial cells.
Asthma risk increases in children treated for HIV
Children whose immune systems rebound after treatment with potent anti-viral drugs for HIV infection face an increased risk of developing asthma, said a federally funded consortium of researchers led by those from Baylor College of Medicine in a report that appears online in the Journal of Allergy and Clinical Immunology.
Findings offer insights into role of breastfeeding in preventing infant death, HIV infection
In many poor countries, mothers with HIV face a stark choice: to nurse their infants, and risk passing on HIV through their breast milk-or to formula feed, and deprive their infants of much of the natural immunity needed to protect against fatal diseases of early infancy.
HIV drugs, Abacavir and Didanosine, increase the risk of heart attack
A study to assess the adverse effects of anti-retroviral drugs shows that two of the widely used HIV drugs are associated with an increased risk of heart attack/the formation of blood clots in the heart. With the use of Didanosine; the risk of developing a heart attack increases by 49%, with Abacavir; the increased risk is 90%.
HIV drug resistance risk in mothers reduced by combination of common drugs
New research from the University of Alabama at Birmingham (UAB) shows that adding a single dose of two common anti-HIV drugs can prevent HIV-positive pregnant women from developing resistance to an entire class of drugs, potentially improving future treatment options.
HIV is a 'double hit' to the brain
New evidence reported in the August issue of Cell Stem Cell, a publication of Cell Press, offers a novel perspective on how the HIV/AIDS virus leads to learning and memory deficits, a condition known as HIV-associated dementia.
Hepatitis B drug can compromise HIV treatment
Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal.
More Anti-HIV Drugs Current Events and Anti-HIV Drugs News Articles
|
FDA APPROVES GILEAD'S ANTI-HIV DRUG VIREAD.: An article from: Biotech Business by Worldwide Videotex (Publisher) This digital document is an article from Biotech Business, published by Worldwide Videotex on December 1, 2001. The length of the article is 1206 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: FDA APPROVES GILEAD'S ANTI-HIV DRUG VIREAD. Publication: Biotech Business (Newsletter) Date: December 1, 2001 Publisher: Worldwide Videotex Volume: 14 Issue: 12 Page: NA Distributed by Thomson Gale | |
 |
AIDS in Africa Also With: MacNeil / Lehrer Productions (Producer) The AIDS crisis in Africa is the subject of this 2001 NewsHour series. Correspondents report on the situation in three countries: Malawi, Botswana and Senegal. Also included is a discussion about the international community's role in combating the epidemic. A warning: segments in the series contain strong images and frank conversations about sexual habits. |
 |
Red Awareness Ribbon Window Decal by Cool Custom Design Red vinyl precision cut window decal. Applies easily to any smooth surface that is flat or has a simple curve. Ideal for windows, mirrors, signs, vehicles and more. The vinyl is designed for a minimum of 6 years of outdoor durability. Includes simple application instructions. The black area in the image shown represents the surface the decal is applied to. This is a decal that sticks, not one that is static cling. |
|
Two new anti-HIV drugs provide effective combo.(Infectious Diseases): An article from: Family Practice News by Mitchel L. Zoler (Author) This digital document is an article from Family Practice News, published by International Medical News Group on February 1, 2005. The length of the article is 575 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Two new anti-HIV drugs provide effective combo.(Infectious Diseases) Author: Mitchel L. Zoler Publication: Family Practice News (Magazine/Journal) Date: February 1, 2005 Publisher: International Medical News Group Volume: 35 Issue: 3 Page: 32(1) Distributed by Thomson... | |
|
T-20, New Kind of Anti-HIV Drug, Looks Good.: An article from: Family Practice News by Mitchel L. Zoler (Author) This digital document is an article from Family Practice News, published by International Medical News Group on February 15, 2000. The length of the article is 2725 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: T-20, New Kind of Anti-HIV Drug, Looks Good. Author: Mitchel L. Zoler Publication: Family Practice News (Magazine/Journal) Date: February 15, 2000 Publisher: International Medical News Group Volume: 30 Issue: 4 Page: 67 Distributed by Thomson... | |
|
The next line of attack: the previous generation of anti-HIV drugs changed AIDS from an untreatable epidemic into a survivable disease. The next crop aims ... (The national gay & lesbian newsmagazine) by Fred Kuhr (Author) This digital document is an article from The Advocate (The national gay & lesbian newsmagazine), published by Thomson Gale on April 10, 2007. The length of the article is 902 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: The next line of attack: the previous generation of anti-HIV drugs changed AIDS from an untreatable epidemic into a survivable disease. The next crop aims to get rid of the virus altogether.(HEALTH) Author: Fred Kuhr Publication: The Advocate (The national gay & lesbian newsmagazine) (Magazine/Journal) Date: April 10, 2007 Publisher: Thomson... | |
|
Blood fat levels and anti-HIV drugs: now what?: An article from: HIV Treatment: ALERTS! by Ben J. Barnett (Author), Mario Maldonado (Author) This digital document is an article from HIV Treatment: ALERTS!, published by The Center for AIDS: Hope & Remembrance Project on July 1, 2001. The length of the article is 1960 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Blood fat levels and anti-HIV drugs: now what? Author: Ben J. Barnett Publication: HIV Treatment: ALERTS! (Newsletter) Date: July 1, 2001 Publisher: The Center for AIDS: Hope & Remembrance Project Page: 6(4) Distributed by Thomson... | |
|
Anti-HIV Agents, Drugs and Substances: Index and Medical Analysis of New Research Information by Abbe Research Division (Author) | |
|
Antidepressants may enhance anti-HIV activity.(drug use): An article from: Clinical Psychiatry News by Damian McNamara (Author) This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on May 1, 2006. The length of the article is 613 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Antidepressants may enhance anti-HIV activity.(drug use) Author: Damian McNamara Publication: Clinical Psychiatry News (Magazine/Journal) Date: May 1, 2006 Publisher: Thomson Gale Volume: 34 Issue: 5 Page: 72(1) Distributed by Thomson... | |
|
Tenofovir good add-on drug for resistant HIV infections. (New Anti-HIV Therapy).(Brief Article): An article from: Internal Medicine News by International Medical News Group (Publisher) This digital document is an article from Internal Medicine News, published by International Medical News Group on March 1, 2002. The length of the article is 498 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Tenofovir good add-on drug for resistant HIV infections. (New Anti-HIV Therapy).(Brief Article) Publication: Internal Medicine News (Magazine/Journal) Date: March 1, 2002 Publisher: International Medical News Group Volume: 35 Issue: 5 Page: 26(1) Article Type: Brief Article Distributed by Thomson... |
| © 2009 BrightSurf.com |